Integra Ventures
VC Fund
Seattle, United States
Integra Ventures is a VC fund in Seattle focused on Biotechnology and Health Care. Integra Ventures seek investments in Life Science companies in three principal areas: Drug Development, Medical Devices, and Healthcare Services. They consider business plans from experienced entrepreneurs passionately pursuing disruptive opportunities that fulfill large unmet medical or market needs.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Integra Ventures invests in
BiotechnologyHealth CareMedicalPharmaceuticalGenetics
Stages Integra Ventures invests in
Series DFunding RoundSeries BSeries C
Countries Integra Ventures invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Hans M. Lundin
|
|||
|
James Nelson
|
|||
|
Joseph Piper
|
|||
|
Timothy Thompson Black
|
|||
Investment Focus
Industry
- Biotechnology 6 (60%)
- Health Care 4 (40%)
- Medical 3 (30%)
- Pharmaceutical 3 (30%)
- Genetics 2 (20%)
Stage
- Series D 5 (50%)
- Funding Round 2 (20%)
- Series B 1 (10%)
- Series C 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Hans M. Lundin
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
|
James Nelson
Partner
|
Partner | Total investments: 0 | Find email | |
|
Joseph Piper
Founder and Managing Director
|
Founder and Managing Director | Total investments: 0 | Find email | |
|
Timothy Thompson Black
Chief Operating Officer
|
Chief Operating Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| PLx Pharma is a pharmaceutical company that develops and commercializes non-steroidal anti-inflammatory drugs (NSAIDs) for prescription and over-the-counter markets in the United States. The company offers PL2200 Aspirin, a molecular complex of aspirin and phosphatidylcholine; and PL1100/1200 Ibuprofen, which are oral drug products containinga molecular complex of ibuprofen and phosphatidylcholine. | $8.3M / May 23, 2013 | ||
| Wellpartner is a nationally recognized provider of pharmacy distribution solutions for health plans, Medicaid programs, and safety net organizations throughout the country. Dedicated to lowering the cost of medications, we offer innovative approaches that improve pharmacy care for individuals through the use of retail contract pharmacy services. Weare the largest independent provider of contract pharmacy program services in the nation. | $16.1M / Series D / Aug 05, 2008 | ||
| Tepha is a medical device firm pursuing the development and commercialization of innovative products based on the company's proprietary biomaterial technology. The technology provides a new class of absorbable biomaterials, known as polyhydroxyalkanoates , which may be tailored to meet unmet needs for medical devices in multiple fields.Tepha's novel, biosynthetically produced materials offer superior performance in flexibility, elasticity, and biocompatibility; and, for its fiber-based products, excellent tensile strength and strength retention. | $10.7M / Series B / Jun 06, 2007 | ||
| Blue Heron Biotechnology has been a pioneer and leader of the gene synthesis market since its founding in 1999. Blue Heron provides the broadest range of synthetic DNA sequences and related services to thousands of researchers across multiple industries, including 19 of the top 20 pharmaceutical and biotechnology companies. | $3.7M / Series D / Jan 16, 2007 | ||
| Calypso Medical Technologies is a Seattle-based, privately held medical device company. The Company's proprietary tumor localization system utilizes miniaturized implanted devices (Beacon® electromagnetic transponders) to continuously, accurately and objectively track the location of tumors for improved accuracy and management of radiationtherapy delivery. The technology is designed for body-wide cancers commonly treated with radiation therapy. The products are FDA 510(k) cleared for use in the prostate and post-operative prostatic bed. The Company has strategic relationships with Varian Medical Systems, Siemens Medical Systems, Elekta Corporation, and Philips Medical. | $42.2M / Series D / Jan 08, 2007 | ||
| Targeted Growth is a crop-biotech company developing yield-enhanced and quality-improved products for the agriculture and energy industries. TGI's crop biotechnology increases the yields in multiple crops and it focuses on those crops such as corn, soy, and canola that produce the raw material that enables farmers to use them for theproduction of renewable fuels such as ethanol and biodiesel. | $10M / Series D / May 22, 2006 | ||
| Raven biotechnologies, Inc., a biotechnology company, focuses on the development of monoclonal antibody therapeutics for treating cancer. Its lead product candidate, RAV12, targets adenocarcinomas and used for the treatment of gastrointestinal, lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. The company was founded in 1999 andis based in South San Francisco, California. As of July 17, 2008, Raven Biotechnologies, Inc. operates as a subsidiary of MacroGenics, Inc. | $48.3M / Series D / Oct 24, 2005 | ||
| Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of thecompany are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma.Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006. | $65M / Series C / Apr 13, 2004 | ||
| Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of thecompany are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma.Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006. | $40M / Series B / Mar 07, 2003 | ||
| Amnis Corporation engages in the development, manufacture, and marketing of cell analysis systems for the imaging and analysis of cells in flow. It provides ImageStream, an instrument that combines the functionalities of microscopy and flow cytometry in a single platform for various applications in drug discovery, basic biomedical research, anddiagnostics. The company also offers upgrades for ImageStream system to add additional functionality, including violet and red lasers, and an extended depth of field technology (EDF) option. In addition, it provides IDEAS, a cell image analysis software that is used for the quantitative analysis of cell images, as well as for the evaluation of image-based data in various cell populations. Further, the company provides a calibration reagent for the operation of ImageStream system that allows the instrument to track flow rate and core position; and a sheath solution for the functioning of ImageStream system. Its systems are used in apoptosis, immune synapse analysis, nuclear translocation, leukocyte classification, cell cycle analysis, cell morphology analysis, intracellular molecular trafficking, surface markers co-localization, and gene expression quantitation applications. The company offers its products to academic, biotechnology, and pharmaceutical customers. Amnis Corporation was founded in 1998 and is headquartered in Seattle, Washington. | $8.8M / Dec 02, 2001 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
Health Care Investors
47,147 investors
Biotech Investors
23,541 investors
Biotechnology Investors
20,889 investors
Medical Investors
20,530 investors
Health Care VC Funds
35,356 investors
Biotech VC Funds
20,362 investors
Biotechnology VC Funds
18,327 investors
Medical VC Funds
17,653 investors
Health Care Investors in United States
21,541 investors
FAQ
What does Integra Ventures invest in?
Integra Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series D and Funding Round stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Integra Ventures?
Public channels for Integra Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Integra Ventures?
The team at Integra Ventures includes Hans M. Lundin (Chief Financial Officer), James Nelson (Partner) and Joseph Piper (Founder and Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
